Literature DB >> 8421335

Risks and benefits of femoropopliteal percutaneous balloon angioplasty.

M G Hunink1, M C Donaldson, M F Meyerovitz, J F Polak, A D Whittemore, K Kandarpa, C J Grassi, J Aruny, D P Harrington, J A Mannick.   

Abstract

PURPOSE: The purpose of this study was to evaluate the efficacy of angioplasty in the treatment of femoropopliteal arterial disease.
METHODS: From 1980 to 1991, 126 angioplasty procedures were performed in 131 limbs of 106 patients with 175 femoropopliteal lesions (26 common femoral, 118 superficial femoral, and 31 popliteal). Critical ischemia was present in 55 limbs (42%), and claudication was present in 76 (58%). Angioplasty was performed for a single lesion in 87 limbs (66%) and for multiple lesions in 44 (34%). In 13 limbs (10%) the most severe lesion was an occlusion; in 118 (90%) all lesions were stenoses. Distal runoff was good (2 or 3 vessels patent) in 72 limbs (55%) and poor (0 or 1 vessel patent) in 59 (45%).
RESULTS: Death within 30 days occurred in 0.8%, nonfatal systemic morbidity in 7.1%, and local morbidity in 1.6% of procedures. Multivariate analysis revealed that indication and age were predictive of increased morbidity and mortality rates. Immediate success was achieved in 95% of limbs treated. Mean follow-up time was 2.0 years. The overall 5-year cumulative primary patency rate was 45% (+/- 5%). In a proportional hazards model indication and lesion type were predictive (p < 0.01) of long-term failure, with relative risks of 2.0 (1.2 to 3.3) and 2.7 (1.3 to 5.6), respectively. The 5-year primary patency rate after angioplasty for stenoses and claudication was 55% (+/- 7%), for stenoses and critical ischemia it was 29% (+/- 11%), and for occlusions it was 36% (+/- 14%).
CONCLUSION: These results suggest that femoropopliteal angioplasty is a low-risk procedure with acceptable long-term results in patients with claudication and stenoses.

Entities:  

Mesh:

Year:  1993        PMID: 8421335

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  9 in total

Review 1.  An overview of optimal endovascular strategy in treating the femoropopliteal artery: mechanical, biological, and procedural factors.

Authors:  Nicolas W Shammas
Journal:  Int J Angiol       Date:  2013-03

2.  Lower Extremity Arterial Occlusive Disease: Role of Percutaneous Revascularization.

Authors:  Ronak S Kanani; Joseph M Garasic
Journal:  Curr Treat Options Cardiovasc Med       Date:  2005-06

3.  Vascular surgical intervention for complications of cardiovascular radiology: 13 years' experience in a single centre.

Authors:  D R Lewis; R A Bullbulia; P Murphy; A J Jones; F C Smith; R N Baird; P M Lamont
Journal:  Ann R Coll Surg Engl       Date:  1999-01       Impact factor: 1.891

4.  Long-term clinical outcome following lower limb arterial angioplasty.

Authors:  G Morris-Stiff; M Moawad; N Appleton; G Davies; E Hicks; C Davies; M H Lewis
Journal:  Ann R Coll Surg Engl       Date:  2011-04       Impact factor: 1.891

5.  Stent placement for superficial femoral arterial occlusive disease in high-risk patients: preliminary results.

Authors:  Toshiya Nishibe; Yuka Kondo; Masayasu Nishibe; Akihito Muto; Alan Dardik
Journal:  Surg Today       Date:  2009-01-08       Impact factor: 2.549

Review 6.  Update on paclitaxel for femoral-popliteal occlusive disease in the 15 months following a summary level meta-analysis demonstrated increased risk of late mortality and dose response to paclitaxel.

Authors:  Peter A Schneider; Ramon L Varcoe; Eric Secemsky; Marc Schermerhorn; Andrew Holden
Journal:  J Vasc Surg       Date:  2020-09-02       Impact factor: 4.268

7.  Midterm Outcome of Femoral Artery Stenting and Factors Affecting Patency.

Authors:  Jae Seoung Yu; Keun-Myoung Park; Yong Sun Jeon; Soon Gu Cho; Kee Chun Hong; Woo Young Shin; Yun-Mee Choe; Seok-Hwan Shin; Kyung Rae Kim
Journal:  Vasc Specialist Int       Date:  2015-12-31

8.  The Effect of Severe Femoropopliteal Arterial Calcification on the Treatment Outcome of Femoropopliteal Intervention in Patients with Ischemic Tissue Loss.

Authors:  Hyun Yong Lee; Ui Jun Park; Hyoung Tae Kim; Young-Nam Roh
Journal:  Vasc Specialist Int       Date:  2020-06-30

9.  Is Paclitaxel Causing Mortality During Lower-Extremity Revascularization?

Authors:  Rajesh V Swaminathan; W Schuyler Jones; Manesh R Patel
Journal:  J Am Heart Assoc       Date:  2019-05-21       Impact factor: 5.501

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.